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1. Introduction 
Cholestasis, caused by the interrupted excretion of bile, resulting in an accumulation of bile 
products in the body fluids is characteristic of many human liver diseases (Sherlock & 
Dooley, 1997). Experimental animal models of cholestasis allow the understanding of 
pathophysiological mechanisms involved and their clinical correlates (Chang et al., 2005; 
Chandra & Brower, 2004). The most common experimental models of intrahepatic 
cholestasis are estrogen-induced, endotoxin-induced and drug-induced cholestasis 
(Rodriguez-Garay, 2003). Drug-induced cholestasis was described during treatment by 
different drugs in medical clinic and in experimental research. In experimental medicine, ǂ-
naphthylisothiocyanate (ANIT) treatment has been extensively used, permitting to describe 
not only cholestatic alterations but also compensatory mechanisms. The animal model and 
transport protein studies are necessary for the progressive understanding of congenital and 
acquired human cholestasis, and regulatory mechanisms which operate on liver cells. 
Continuous bile formation is an important function of the liver, and bile is used as a vehicle 
for the secretion of bile acids and the excretion of lipophilic endo- and xenobiotics (Meier 
and Stieger, 2000; Hsien et al., 2006). Molecular and cellular mechanisms of intrahepatic 
cholestasis development are important for understanding of role of different factors in this 
process and effective therapy. Lysosomes are connected with bile secretion, however their 
role in cholestasis development is still not clear. Human bile revealed high activity of 
lysosomal enzymes (ǃ-galactosidase, ǃ-N-acetylglucosaminidase, acid phosphatase) which 
are suggested to be secreted from lysosomes localized in peribiliar zone of hepatocytes 
(Korolenko et al., 2007). We tested the hypothesis that impaired lysosomal secretion is 
related to cholestasis development. Earlier in some works it was shown that in mice and rats 
increased activity of lysosomal enzymes in bile was connected with their increased 
secretion. 
The aim: to study the mechanism of intrahepatic cholestasis development and the role of 
lysosomes in bile secretion and cholestasis development. The following models of 
experimental cholestasis have been used and analyzed in our study: known model of 
intrahepatic cholestasis induced by ǂ–naphtylisothyocyanate (ANIT) and lysosomotropic 
agent Triton WR 1339. 
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2. Drugs induced cholestasis and lysosomotropic agents 
In inflammatory disorders such as sepsis, bacterial infections, viral hepatitis as well as toxic 
or drug-induced hepatitis, inflammatory cytokines can impair bile secretion (Jansen & 
Sturm, 2003; Paumgartner, 2006). Intrahepatic cholestasis of different pathomechanisms was 
shown to develop during treatment by several medical drugs (Krell et al., 1987), some of 
them possessed by lysosomotropic action. According to concept of de Duve et al. (1974) 
lysosomotropic agents are selectively taken up into lysosomes following their 
administration to man and animals (Schneider et al., 1997). The effects of lysosomotropic 
drugs studied in vivo and in vitro can be used as models of lysosomal storage diseases. These 
agents include many drugs still used in clinical medicine: aminoglycoside antibiotics, 
flouroquin antimicrobial agents (ciprofloxacin), amoxicillin/clavulanic acid, phenothiazine 
derivatives, antiparasitic and anti-inflammatory drugs (chloroquine and suramin, gold 
sodium thiomalate) and cardiotonic drugs like sulmazol (Schneider et al., 1997). Side-effects 
to these drugs can be caused partially by their lysosomotropic properties. In addition to 
drugs, other compounds to which man and animals are exposed (e.g., heavy metals, iron 
compounds, lantan and gadolinium salts, some cytostatics) are also lysosomotropic. Liver 
cells, especially Kupffer cells, are known to accumulate lysosomotropic agents. We present 
our studies which evaluate lysosomal changes in the liver following administration of 
lysosomotropic agents in experimental animals, and relate them to toxic side-effects or 
pharmacological action, as was suggested earlier (de Duve et al., 1974). Common features of 
lysosomal changes include the overload of liver lysosomes by non-digestible material; 
increased size and number of liver lysosomes; inhibition of several lysosomal enzymes; 
secondary increase in the activity of some lysosomal enzymes; increased autophagy, and 
fusion disturbances.  
2.1 Biochemical component of bile of intact CBA/C57BL mice  
2.1.1 Experimental animals and methods used 
All animal procedures were carried out in accordance to approved protocol and 
recommendations for proper use and care of laboratory animals (European Communities 
Council Directive 86/609/CEE). Experiments were performed on male CBA/C57BL/6 mice 
weighting 25-30 g (Institute of Physiology, Siberian Branch of Russian Academy of Medical 
Sciences, Novosibirsk). To reproduce the model of intrahepatic cholestasis corn oil solution of 
ANIT was injected intraperitoneally in a single dose of 200 mg/kg (0.2 ml per mouse) (Kodali 
et al., 2006). The animals were euthanized 24 h after ANIT injection. Triton WR 1339 (Ruger 
Chemical Co, USA) was dissolved in physiological saline solution and injected 
intraperitoneally in a single dose of 500 and 1000 mg/kg. The mice were decapitated 24 and 72 
h after Triton WR 1339 administration (when significant accumulation of detergent occurred 
inside of lysosomes). Oil solution of hepatotoxin carbon tetrachloride (CCl4, 50 mg/kg) was 
administered intraperitoneally, as a single injection. The mice were used in experiment 24, 48 
and 72 h after CCl4 intoxication. The separate group of animals received Triton WR 1339 two 
hours before administration of CCl4 in a dose indicated (combined treatment). The mice were 
deprived of food (15 h before decapitation), but received water ad libidum. Blood serum was 
obtained by centrifugation of samples at 3000 g, +4° C for 20 minutes, using Eppendorf 5415 R 
centrifuge (Germany). The bile was taken from gall bladder using a microsyringe; the bile 
samples from 5 mice were combined to measure the lysosomal enzyme activity. 
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Serum and bile alanine transaminase (ALT) activity (serum marker of hepatocyte cytolisis) 
was measured with help of commercial Lachema Diagnostica kits (Czech Republic). Activity 
of alkaline phosphatase and Ǆ-glutamyltransferase (GGTP) were measured using Vital 
Diagnostics kits (Saint Petersburg, Russia). The increase of serum activity of alkaline 
phosphatase and GGTP reflects the development of intrahepatic cholestasis in mice. 
Fluorescent methods were used to measure the following lysosomal enzyme activity: ǃ-D-
galactosidase (high specific activity in hepatocytes) in the bile and serum using 4-
methylumbellipheryl-ǃ-D-galactopyranoside as a substrate (Melford Laboratories Ltd, 
Suffolk, UK); ǃ-hexosaminidase or ǃ-N-acetylglucosaminidase (4-MUF-2-acetamido-2-
deoxy-ǃ-D-glucopyranoside, Melford Laboratories Ltd. Suffolk, UK) and chitotriosidase - 4-
MUF-ǃ-D-N,N’, N’’-triacetylchitotrioside (Sigma). Fluorescence of samples was measured 
on Perkin Elmer 650-10S spectrofluorometer at the exitation and emission wavelengths of 
360 and 445 nm, respectively. The results were expressed in µmol methylumbelliferone 
released per liter in min. The data obtained were analyzed statistically, using Student t-test; 
the differences between the means were significant at p< 0.05. 
Electron microscopic study of liver cells was provided according to method described by 
Trout and Viles (1979). 
2.1.2 Composition of bile and serum of intact mice 
In bile of intact CBA/C57BL mice comparatively to serum the total protein was significantly 
decreased (more than 60-times), as well as albumin concentration (Table 1); alkaline 
phosphatase activity in bile is significantly lower as in serum, whereas similar level of ALT 
activity was noted; AST activity in bile was reduced about twice comparatively to serum of 
the same animals (Table 1). Activity of lysosomal enzyme ǃ-D-galactosidase was similar in 
serum and bile of mice (Table 1). One can conclude that murine bile possessed relatively 
high activity of lysosomal enzyme as well as ALT and AST activity. 
 
Index Serum Bile 
Total protein, g/L 65.8 ± 2.96 1.140 ± 0.006 
Albumin, g/L 30.4 ± 0.70 0.530 ± 0.005 
ALT activity, U/L 57.2 ± 1.67 45.4 ± 1.00 
AST activity, U/L 201.0 ± 10.60 113.6 ± 14.80 
Alkaline phosphatase activity, U/L 268.0 ± 8.16 48.0 ± 6.00 
ǃ-D-galactosidase activity, µmol MUF/L per h 12.30 ± 1.33 15.6 ± 0.36 
Table 1. Concentration of total protein, albumin and activity of enzymes in serum and bile of 
Intact CBA/C57BL/6 mice 
2.2 ANIT as a model of intrahepatic cholestasis 
Experimental models of cholestasis in laboratory animals allow us to evaluate the 
pathophysiological and molecular mechanisms of this disorder. Some similarities were 
revealed between experimental cholestasis in animals and cholestasis in patients (Moritoki 
et al., 2006; Dold et al., 2009). Experimental cholestasis in rats and more rarely in mice can be 
induced by not only common bile duct ligation, but also by treatment with estrogens, 
endotoxins, and various medical products. Intrahepatic cholestasis induced by ANIT is a 
convenient model for studies of hepatocyte injury and compensatory mechanisms in 
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spontaneous recovery of liver function. Changes in hepatocyte transport proteins and 
dysregulation of bile secretion were revealed in mice with experimental cholestasis (Hsien et 
al., 2006). Cholestasis in mice and rats was observed in the early period after ANIT 
treatment (4-8 h), reaching maximum 24 and 48 h after ANIT administration. The severity of 
cholestasis depended on the dose of ANIT, route and regimen of treatment, and basal level 
of cytokines (tumor necrosis factor-ǂ, TNF-ǂ). Repeated administration of ANIT to mice is 
accompanied by the development of biliary cirrhosis; the mechanism of this phenomenon 
remains unclear (Ferreira et al, 2003). 
ANIT is a known hepatotoxic agent that causes acute cholestatic hepatitis with infiltration of 
neutrophils around bile ducts and necrotic hepatocytes (Kodali et al., 2006; Luyendyk et al., 
2011). In this work lysosomal enzyme activity in the bile and blood serum was compared in 
mice with known experimental intrahepatic cholestasis model induced by ANIT and by 
lysosomotropic agent Triton WR 1339. ANIT (Aldrich, USA) was administered to mice as an 
oil solution i.p., single, in a dose of 200 mg/kg. The increase in the concentration of total 
bilirubin (86.2±8.6 versus 9.9±0.8 mmol/L in the control, p<0.001) and conjugated bilirubin 
(45.6±4.3 versus 6.10±0.39 mmol/L in the control, p<0.001) in blood serum reflected the 
development of cholestasis in mice. The development of intrahepatic cholestasis was 
confirmed by the increase in activity of alkaline phosphatase and Ǆ-glutamyltransferase 
(GGTP) in blood serum. ǃ–Galactosidase, ǃ-hexosaminidase and chitotriosidase activity 
significantly increased in the bile, but decreased in the serum of mice after treatment with 
ANIT (Table 2). Our results indicate that intrahepatic cholestasis is manifested in increased 
secretion of lysosomal glycosidases into the bile. It was suggested that bile components can 
aggravate damage to liver cells by affecting the processes of hepatocyte apoptosis and 
necrosis. ANIT dramatically increased serum GGTP activity (Figure 1), indicating severe 
cholestasis development according to ALT and AST (Figure 3); there was no change of urine 
creatinine and uroprotein concentrations (Figure 2). Our results indicate that hepatocyte injury 
and cholestasis are observed 24 h after ANIT treatment. Total cholesterol concentration 
increased in blood serum (Figure 4A). Triglyceride level increased, while cholesterol 
concentration decreased in the bile (Figure 4B). Cholesterol serves as a common precursor of 
bile acids. The ANIT-induced increase in serum cholesterol concentration reflects lipid 
metabolism disorder, which is manifested in lipid infiltration of the liver and cholestasis. 
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Fig. 1. Effect of ANIT on serum GGTP activity in mice 
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Fig. 2. Effect of ANIT on concentration of creatinine and uroprotein in urine of mice 
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Fig. 3. Effect of ANIT administration in mice on serum ALT, AST and alkaline phosphatase 
activity 
2.2.1 Electron microscopic study of liver (ANIT) 
In situ, the increase of gall bladder size of mice was shown (10 µL bile versus 5 µL in intact 
animals); the color of bile was bright yellow. In general, significant ultrastructural changes 
in liver cells and microcirculatory region were noted. There was heterogeneity among 
hepatocyte injury: cells with normal ultrastructure and hepatocytes revealing dystrophic 
changes were observed. Sinusoids were enlarged, the sinusoidal surface of cells was smooth 
and revealed only small amount of microvilli. The secretory cell function connected with 
bile formation was suppressed. The significant dilatation of bile capillaries (Figure 5, 6) was 
observed, the bile duct had increased oval shape; numerous membraneus material was often 
noted inside of bile ducts. These electron microscopic data confirmed intrahepatic 
cholestasis development. In general, liver cell damage included the enlargement of 
sinusoids and intercellular spaces; enlargement of bile ducts; suppression of protein 
synthesis in hepatocytes and their dystrophic changes.  
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Fig. 4. Concentration of cholesterol, TG and total protein in serum (A) and bile (B) of mice 
with ANIT administration 
2.3 Triton WR 1339t and cholestasis 
2.3.1 Triton WR 1339 as a lysosomotropic drug 
Triton WR 1339 is non-ionic detergent widely used for isolation of lysosomes (triton-filled 
lysosomes, tritosomes) in cellular biochemistry (de Duve et al., 1974; Trout and Viles, 1979). 
Earlier Triton WR 1339 (Tyloxapol) shortly used as a medical drug for treatment of 
bronchitis. In vivo in the doses of 300-1000 mg/kg Triton WR 1339 is taken up by liver cells 
(mainly by macrophages) and accumulated inside of lysosomes during long period, up to 60 
days after the single administration to rats and mice (Schneider et al., 1997). Simultaneously, 
Triton WR 1339 was shown to induce significant hypercholesterolemia and, especially, 
hypertriglyceridemia in rats and mice and other laboratory animals, in a dose-dependent 
manner (Abe et al., 2007; Korolenko et al., 2011). Triton WR 1339 administration to mice (500 
mg/kg) was shown to induce significant lipemia sharply increasing both the total 
lipoprotein-cholesterol and total lipoprotein-triglyceride concentrations in serum of mice. 
However, the increase in total lipoprotein-triglycerides was much more dramatic (about  
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Fig. 5. Hepatocytes of mice with ANIT administration. Enlarged bile capillary (BC), 
hepatocytes (H) contains enlarged cisterns of endoplasmic reticulum (arrows). X 20 000. 
 
Fig. 6. Electronogram of liver of mice with ANIT administration. Enlarged sinusoid (S) and 
enlarged bile capillary (BC), hepatocytes contains large vacuoles (arrows). X 20 000. 
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10-times) than the elevation of the total lipoprotein-cholesterol (about 5-times), relative to 
control (intact) mice (Korolenko et al., 2011). The Triton WR 1339 hyperlipidemic mouse 
model is a widely used model for inhibition of lysosomal lipolysis and evaluation of 
different hypolipidemic drugs (Abe et al., 2007). It was shown that accumulation of Triton 
WR 1339 occurred simultaneously with some serum lipoproteins inside of liver lysosomes. 
Triton WR 1339 administration to mice and rats was shown to increase cholesterol synthesis 
(fatty acids precursor) in liver cells. Possibly, significant hypercholesterolemia induced by 
Triton WR 1339 administration to mice was related to cholestasis development (presented 
below), which is not known enough in literature. 
2.3.2 Biochemical characteristic of Triton WR 1339-induced cholestasis in mice 
Triton WR 1339 (Ruger Chemical Co., USA) was administered in mice as a single injection, 
i.p., in a dose of 100 mg/100 g, the appropriate animals received the same volume of saline 
solution. Mice were decapitated 24, 48, 72 h after the single injection. CBA/C57BL/6 male 
mice of weight 26.8 ± 0.40 g were used. Single administration of Triton WR 1339 (500 
mg/kg) in mice was followed by significant increase in concentrations of total cholesterol, 
TG in serum without changes of the total protein concentration (Figure 7 A). In bile, on the 
contrary there were no changes of cholesterol and TG level (Figure 7 B); the increase of the 
total protein concentration was noted in bile. 
In mice treated by Triton WR 1339 (500 mg/kg) intrahepatic cholestasis development was 
confirmed by increased level of serum alkaline phosphatase and GGTP activity (Figure 8). 
The size of gall-bladder in situ was increased, the bile had yellow color. According to 
electron microscopy study of liver cells numerous triton-filled lysosomes were observed in 
non-parenchymal (especially in Kupffer cells) and parenchymal cells (Figure 9, 10); 
enlargement of bile ducts was noted as well as other morphological signs of intrahepatic 
cholestasis. However, in general the enlargement of bile ducts was shown in a less degree as 
compare to ANIT-induced model of cholestasis.  
2.3.3 The comparison of serum and bile lysosomal enzymes in Triton WR- and ANIT-
induced models of cholestasis 
The following lysosomal enzymes were compared in two cholestasis models studied: ǃ-D-
galactosidase, ǃ-hexosaminidase and chitotriosidase. In intact mice we observed similar 
activity of ǃ-D-galactosidase in serum and bile, whereas activity of ǃ-hexosaminidase was 
significantly higher in serum (about 40-times) as compare to bile, as well as chitotriosidase 
activity (about 6-times higher in serum comparatively to bile) (Table 2). Both models of 
cholestasis were characterized by decreased ǃ-D-galactosidase and ǃ-hexosaminidase 
activity in serum (Table 2). However, serum chitotriosidase activity increased in ANIT 
model and decreased in Triton WR 1339-induced cholestasis (Table 2). In bile all lysosomal 
enzymes studied - ǃ-D-galactosidase, ǃ-hexosaminidase and chitotriosidase activity were 
significantly increased (Table 2), especially ǃ-D-galactosidase (about 10-times higher in bile 
as compare to serum in Triton WR 1339-treated mice (Table 2). In ANIT model we observed 
higher chitotriosidase activity in bile as compare to Triton WR 1339. 
So, both models studied were characterized by increased level of lysosomal enzymes in bile. 
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Group/Index Serum Bile 
Intact (ǃ-D–galactosidase, MUF/L per h) 12.3 ± 1.33 12.30 ± 1.63 
Triton WR 1339 (ǃ-D-galactosidase, , MUF/L per h ) 6.1 ± 0.60 * 117.3 ± 1.40* 
ANIT (ǃ-D-galactosidase, , MUF/L per h) 4.6 ± 0.32* 22.2 ± 0.34* 
Intact (ǃ-hexosaminidase, µmol MUF/L per min) 7.9 ± 0.95 0.54 ± 0.07 
Triton WR 1339 (ǃ-hexosaminidase, µmol MUF/L per min) 4.0 ± 0.47* 2.5 ± 0.20* 
ANIT (ǃ-hexosaminidase, µmol MUF/L per min) 1.52 ± 0.05* 1.57 ± 0.10* 
Intact (chitotriosidase, µmol MUF/L per min ) 20.50 ± 2.79 3.40 ± 0.28 
Triton WR 1339 (chitotriosidase, µmol MUF/L per min) 8.90 ± 0.81* 11.85 ± 0.40* 
ANIT (chitotriosidase, µmol MUF/L per min) 35.0 ± 2.79* 17.50 ± 3.56* 
Table 2. Effect of Triton WR 1339 and ANIT on activity of lysosomal enzymes in serum and 
bile of mice 
*p < 0.01 vs control (intact mice) 
Triton WR 1339, 1000 mg/kg, 72 h.  ANIT, 200 mg/kg, 24 h. MUF- methylumbelliferyl. 
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Fig. 7. Effect of Triton WR 1339 administration in mice on serum (A) and bile (B) cholesterol, 
TG and total protein concentration 
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Fig. 8. Effect of Triton WR 1339 on serum alkaline phosphatase (AP) and GGTP activity in 
intact mice and with acute toxic hepatitis  
 
 
 
 
Fig. 9. Electronogram of liver macrophage, triton-filled lysosomes. Triton WR 1339, 1000 
mg/kg, 72 h. X 20 000. 
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Fig. 10. Electronogram of liver macrophage, Triton WR 1339, 1000 mg/kg, 48 h; enlarged 
macrophage with numerous triton-filled lysosomes. X 20 000 
2.4 Effect of Triton WR 1339 on liver cells ultrastructure 
Macroscopically, in situ; bile color was bright yellow. The morphological changes of liver 
cells under Triton WR 1339 administration in rats and mice were described earlier (Trout & 
Viles, 1979; Schneider et al., 1997), however there was no data collected about the 
intrahepatic cholestasis development. As was shown before, we observed numerous triton-
filled lysosomes in Kupffer cells and also in hepatocytes (Figure 9, 10). The ultrastructural 
signs of cholestasis induced by Triton WR 1339 in mice included enlargement of bile duct, 
however these changes were expressed in a lesser degree as compare to ANIT model. 
3. The role of liver macrophage in cholestasis development 
3.1 Macrophage depression model  
Gadolinium chloride is widely used for modeling selective depression of liver macrophages. 
Selective elimination of the subpopulation of large Kupffer cells, inhibition of receptor-
mediated endocytosis and phagocytosis of carbon particles in liver macrophages, increase in 
the number of mRNA transcripts, and stimulation of TNF-ǂ, IL-1, and IL-6 production were 
observed  24-48 h after intravenous injection of gadolinium chloride (Ding et al., 2003). The 
phagocytic function of macrophages recovered and population of liver macrophages was 
restored after 3 and 4 days, respectively. It was hypothesized that the mechanism of 
gadolinium accumulation in lysosomes is similar to that for other lysosomotropic agents. 
This accumulation is accompanied by labilization of lysosomes and leads to cell damage. 
The consequences of intracellular gadolinium accumulation and its effect on lysosomal 
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functions remain unclear. We studied the kinetics of gadolinium accumulation in the liver 
and its effects on liver lysosomes and activity of lysosomal enzymes in blood serum. Among 
lysosomal enzymes we have chosen ǃ-N-acetylhexosaminidase, a marker enzyme of liver 
macrophages, ǃ-D-glucuronidase and ǃ-D-galactosidase, easily solubilized matrix lysosomal 
enzymes, whose activity varies more significantly in comparison with membrane-bound 
enzymes. The suppression of functional activity of Kupffer cells was also followed by the 
changes in activity of blood serum chitotriosidase, a novel macrophage enzyme (Korolenko 
et al, 2008).  
We have shown that accumulation of gadolinium (as lysosomotropic agent) occurred during 
the period of its maximum uptake (the day 1 after gadolinium chloride in vivo injection) 
followed by decrease of its concentration (days 5-37). Accumulation of gadolinium inside of 
lysosomes of liver cells led to structural and functional changes in liver lysosomes. 
Macrophage depression of the affected macrophages was accompanied by a decrease in 
osmotic fragility of lysosomes on the day 2 and increase in their osmotic susceptibility 
during repopulation of macrophages on days 5 and 8. The hypotonic treatment of liver 
homogenates (0.125 M sucrose at 0º C during 30 min) revealed increased free activity of acid 
phosphatase (as a result of the increased number of secondary lysosomes in the whole 
polulation of lysosomes).  
Macrophage depression induced by gadolinium chloride in vivo was used in studies of the 
role of macrophages in different experimental models. In our study, electron microscopy of 
liver cells showed that injection of gadolinium chloride (14 mg/kg) in intact mice was 
followed by a significant decrease in the numerical density (788.0±69.1 vs. 1053.0±60.5 per 
mm2 in the control, p<0.01) and diminished size of liver macrophages. The relative volume 
of primary lysosomes and, especially of secondary lysosomes was significantly lower than 
in the control (1.70 ± 0.64 versus 7.60 ± 1.08% in the control, p<0.01). High concentration of 
gadolinium in the liver was associated mainly with selective intralysosomal accumulation of 
gadolinium in nonparenchymal liver cells (85% of the administered dose, 1 h after 
gadolinium chloride administration). Liver function tests (measured according to serum 
ALT activity) remained unchanged under these conditions. The decrease in the number of 
liver macrophages and lysosomes in these cells was accompanied by a decrease in specific 
activity of lysosomal enzymes - cathepsin D and cathepsin B in liver homogenates. No 
changes were found in activities of cathepsin S, a macrophage-specific cysteine protease 
(Table 3). In serum the total MMP-2 concentration (proenzyme and active enzyme) was also 
decreased; TIMP-1 concentration (major endogenous MMP inhibitor) remained unchanged 
in serum (Table 3). These changes were probably related to interaction between Kupffer cells 
and stellate cells in the liver, which serve as the main source of MMP and TIMP-1.  Our 
results showed that single injection of gadolinium chloride was followed by a decrease in 
activities of lysosomal cysteine (cathepsin B) and aspartyl proteases  (cathepsin D) studied 
(Table 3). The observed changes were possibly associated with a decrease in the number and 
functional activity of Kupffer cells.  
We studied the role of selective suppression of liver Kupffer cells (induced by gadolinium 
chloride, in a dose of 14 mg/kg, intravenously) in the development of intrahepatic 
cholestasis in CBA/C57BL/6 mice ( intraperitoneal injection of ANIT in a single dose of 200 
mg/kg). 
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Index 
Control  
(intact mice) 
Gadolinium chloride, 
14 mg/kg, 24 h 
ALT activity in serum, U/L 54.20 ± 1.55 44.6± 6.10 
Cathepsin B activity (liver) 0.27 ± 0.02 0.20 ± 0.02* 
Cathepsin L activity (liver) 0.46 ± 0.05 0.46 ± 0.03 
Cathepsin S activity (liver) 0.030 ± 0.002 0.030 ± 0.001 
Cathepsin D activity (liver) 0.10 ± 0.08 0.060± 0.007* 
Total MMP-2 concentration in serum, ng/mL 201.5± 4.66 181.70± 4.64* 
Serum TIMP-1 concentration, pg/mL 8000.0 ± 1443.4 8450.0 ± 1472.2 
Table 3. Effect of gadolinium chloride on activity of lysosomal enzymes in liver and serum 
concentrations of MMP-2 and TIMP-1 in mice (M ± m) 
Note: * p<0.05 vs control. Activity of cathepsin B (against fluorogenic substrate Z-Arg-Arg-MCA), 
cathepsin L (substrate Z-Phe-Arg-MCA), cathepsin S (substrate Z-Val-Val-Arg- MCA, Sigma–Aldrich, 
USA) in liver homogenates expressed in nmol MCA/min per  mg of protein. Cathepsin D activity is 
espressed in arbitrary units (A366/min per g of protein). MMP-2 and TIMP-1 concentration was 
measured using commercial ELISA R&D kits.  * p < 0.05  as compared to intact animals 
In the separate experiment it was shown that preliminary administration of gadolinium 
chloride to ANIT-treated animals was followed by an increase in activities of ALT 
(133.5±37.6 vs. 74.70±9.18 U/L in the ANIT group, p=0.005), alkaline phosphatase (269.1±9.1 
vs. 158.6±11.1 U/L in the ANIT group, p=0.0001), and Ǆ-glutamyl transpeptidase in urine 
samples (243.0±10.0 vs. 135.8±30.7 U/L in the ANIT group, p<0.05). Hence, the severity of 
cholestasis and hepatocyte injury increased after combined treatment with gadolinium 
chloride and ANIT. Aggravation of cholestasis under macrophage suppression in ANIT-
treated animals, probably, was associated with the increased secretion of TNF-ǂ. 
Gadolinium chloride exposure was accompanied by changes in protease secretion from 
Kupffer cells and stellate cells, remodeling of the extracellular matrix, and repopulation of 
liver macrophages. Cholestasis and hyperbilirubinemia in ANIT-treated rats had similar 
characteristic (Ferreira et al., 2003) as in mice. In general, this process was more significant 
than the signs observed in patients with cholestasis due to medical treatment by different 
drugs (phenothiazine derivatives, methyltestosterone, estrogens, oral contraceptives, etc.). 
So, in experiment in mice and rats pretreatment with gadolinium chloride increased the 
severity of cholestasis and aggravated liver damage. Gadolinium accumulation in the liver 
(with peak after 24 h) was accompanied by a decrease in activity of proteases (cathepsin D 
and cathepsin B) and concentration of matrix metalloprotease-2 (Table 3) possibly, as a 
result of decreased liver macrophage number. Our observations confirm the hypothesis that 
normal function of Kupffer cells and extracellular matrix plays an important role in 
cholestasis. Administration of gadolinium chloride also serves as a convenient model to 
study the side effects, toxicity, and safety of lanthanides as nanoparticles. 
The model of selective liver macrophage depression was characterized by decreased activity 
of serum chitotriosidase, whereas macrophage stimulation (by zymosan or chito-
carboxymethyl ǃ-1,3-glucans), on the contrary, increased chitotriosidase activity (Korolenko 
et al., 2008). The uptake of gadolinium by liver cells during preliminary (before gadolinium 
chloride) administration of ǃ-1,3-glucans was also increased. It was suggested that the 
model of selective liver macrophage depression is useful for study the protective effects of  
different biological response modifiers such as polysaccharides (ǃ-1,3-glucans) in vivo. 
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3.2 Liver injury and cholestasis 
Bile duct obstruction, cholestasis development is associated with hepatic accumulation of 
leukocytes and liver injury (Gehring et al., 2006). According to our data obtained, the 
development of acute CCl4-hepatitis was accompanied by hepatocyte cytolysis and increase 
in serum ALT activity (72 h after hepatotoxin administration to mice 9.50 ± 0.42, n=10 vs 
control 3.50 ± 0.29 U/L, n=10, p< 0.01), however cholestasis was not found in this model (no 
changes of alkaline phosphatase and GGTP activity in serum of mice comparatively to intact 
animals). During combined treatment by Triton WR 1339 and CCl4 the cholestasis was more 
significant as compare to the group of mice received only Triton WR 1339. The aggravation 
of liver injury induced by Triton WR 1339, possibly, was related to increased damage of 
lysosomes by detergent and cholestasis development. It was shown in combined 
administration of Triton WR 1339+ CCl4, that activity of ǃ-galactosidase (116.8 ± 0.49 µmol 
MUF/L per min) and chitotriosidase (8.4 ± 0.55 µmol MUF/L per min) in bile was higher 
compared to intact mice (Table 2). The role of lysosomal enzymes in bile secretion in mice is 
still not clear. Previous studies showed that in intact mice “synchronous” exocytosis of 
lysosomal glucosidases (ǃ-galactosidase, ǃ-glucuronidase and N-acetyl-ǃ-D-
glucosaminidase) into bile occurred in intact rats (Korolenko et al., 2008). The function of 
lysosomal enzymes in the bile remains unclear. Glucosidases are probably involved into 
degradation of glucuronides. Dramatic increased in ǃ-galactosidase activity and some 
changes in ǃ-hexosaminidase and chitotriosidase in bile of mice with the both models of 
experimental cholestasis (induced by ANIT and Triton WR 1339) probably reflected the 
increased exocytosis of enzymes into bile. Transport disorders and concentration of 
lysosomal enzymes in bile can potentiate the effect of different compounds (lipids and fatty 
acids) excreted into bile independently of lysosomal enzymes. Hepatocytes and bile duct 
cells probably are connected with bile secretion in mice, but in general cellular source of 
lysosomal enzymes in bile and serum is not clear. The main part of plasma proteins in 
mammals (mice and rats) are synthesized in liver cells. In humans, serum chitotriosidase 
was shown to originate partially from macrophages and PMN, however in mice, on the 
contrary, chitotriosidase localized mainly in cells of the gastrointestinal mucosa (Korolenko 
et al., 2007; Aerts et al., 2008) and cellular source of this enzyme in serum and bile is still not 
clear.  
3.3 Chitotriosidase activity in liver pathology 
The special attention was devoted to chitotriosidase and intrahepatic cholestasis. 
Chitotriosidase is a new enzyme which was found in human macrophages (Aerts et al., 
2008). There is limited information on the biological role of chitotriosidase in laboratoty 
animals (mice, rats, rabbits); as in humans, the main function of this enzyme is related to 
innate immunity. It was shown that serum chitotriosidase activity in patients with type I 
Gaucher disease increased up to 100-1000 times and now serves as a diagnostic surrogate 
marker of this disorder. In humans, enzyme activity markedly varies (9-195 nmol MUF/mL 
h) in healthy persons and increases with age (Aerts et al., 2008). Chitotriosidase activity is 
very low in 6.2% young individuals and high in 3.1% individuals. Enzyme activity 
moderately increases (by 2-3 times) in patients with inborn lysosomal storage diseases 
(Krabbe disease, GMI gangliosidose, and Niemann-Pick, type A and B disease). As was 
noted before, human chitotriosidase is mainly synthesized in macrophages; stimulated 
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macrophages produce considerable amounts of chitotriosidase mRNA (Aerts et al., 2008). In 
neutrophil precursors chitotriosidase is synthesized and accumulated in specific granules. 
Chitin, a component of cell walls and membranes in various microorganisms, is the natural 
substrate for chitotriosidase; enzyme cleaves also the synthetic substrate 4-
methylumbelliferyl-(MUF)-ǃ-D-N,N’,N’’.-triacetylchitotrioside. Chitinases of plants protect 
them from various pathogenic fungi, this function is similar to mammalian chitotriosidase. 
Probably, mammalian chitotriosidase also has some protective properties. Functions of 
chitotriosidase need further studies. The role of this enzyme is connected with innate 
immunity and removing of foreign bacteria and fungi, whose membranes include chitin; 
this function of chitotriosidase is of particular interest. In mammals, the biological function 
of serum chitotriosidase, as well as its cell origin in experimental lysosomal storage 
syndrome, is poor understood (possibly, enzyme is originated from the stimulated 
macrophages). Earlier we have shown the increase of chitotriosidase activity in serum of 
experimental animals (mice and rats) in macrophage stimulation (by zymosan, 
carboxymethyl ǃ-glucan), which were taken up by Kupffer cells and stimulate liver 
macrophages and also lung and spleen macrophage pools. Triton WR-1339 administration 
in mice was shown to increase the number of liver macrophages and reproduce lysosomal 
storage syndrome, elevating serum chitotriosidase activity 5-7 days after the single drug 
administration. Thus, macrophage stimulation by ǃ-glucans, Triton WR 1339 moderately 
(1.5-2-times) increased serum chitotriosidase activity in experimental animals (mice and 
rats). However, in these experimental models stimulation of macrophages in rats and mice 
did not dramatically increase chitotriosidase activity as in type I Gaucher disease in human 
serum (i.e. more than by 100-1000-times).  
ǃ-Hexosaminidase is one of glucosidase, which had been studied earlier in serum of  
humans and mice. However, there is limited number of works devoted to secretion of this 
enzyme into bile (possibly, by exocytosis). The most of investigations were devoted to study 
this enzyme in humans. Human plasma contains a high-molecular weight enzyme precursor 
(63kDa) of ǃ-hexosaminidase A and B. The presence of 38 kDa mature enzymes in liver 
lysosomes of mammals is related to processing inside of these particles. The bile of mice 
probably contains mature ǃ-hexosaminidase, which is secreted by exocytosis after enzyme 
processing in lysosomes. 
The development of cholestasis in humans and experimental animals may be also associated 
with metabolic disorders of lipids and lipoproteins and accompanies liver injury of different 
etiology. Releasing of lysosomal enzymes can increase the severity of hepatocyte damage 
under the influence of toxic components from the bile (fatty acids salts), which can exert 
modulatory effect on apoptosis of liver cells. Administration of ANIT is rapidly (8-24 h 
after) followed by reversible damage of the epithelium of bile ducts and serves as a widely 
used model of intrahepatic cholestasis in rats and mice. Macrophage depression by 
gadolinium chloride aggravated the cholestasis development in mice induced by ANIT.  
Preliminary administration of Triton WR 1339 in mice and rats, aggravated the development 
of acute toxic hepatitis induced by CC4. The development of CCl4-induced hepatitis (after 72 
h) was accompanied by hepatocyte cytolysis and increase in plasma ALT activity (9.50±0.42 
U/L per h, n=10; vs. 3.50±0.29 U/L per h in the control, n=10; p<0.01). Cholestasis in acute 
toxic hepatitis was not found under isolated CCl4 administration in mice. However, 
aggravation of cholestasis and especially, liver injury was observed after preliminary 
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administration of Triton WR 1339 to mice with acute toxic hepatitis. The aggravation of 
cholestasis after combined treatment by Triton WR 1339 and CCl4 was probably associated 
with effect of Triton WR 1339 on liver lysosomes. Activities of ǃ-galactosidase (116.80± 0.49 
μmol MUF/L per min, n=5) and chitotriosidase (8.40±0.55 μmol MUF/L per min in bile 
samples from treated animals were significantly higher compared to intact mice and animals 
with isolated administration of Triton WR 1339.  
4. Conclusion 
Intrahepatic cholestasis was shown to develop during treatment by different medical drugs 
(antibiotics, phenothiazine derivaties, anti-inflammatory drugs), some of them possessed by 
lysosomotropic action (these drugs are taken up and selectively concentrated in vivo inside 
of lysosomes). The lysosomotropic action of drugs was shown in medical clinics using some 
antibiotics, iron compounds. In experiment we compared the cholestasis development in 
mice with help of known ANIT model and lysosomotropic agent Triton WR 1339 
administration. We compared these models to reveal the common features of intrahepatic 
cholestasis, during study of bile and serum enzymes in animals with intrahepatic 
cholestasis. Intrahepatic cholestasis development was confirmed by elevation of serum 
alkaline phosphatase and Ǆ–glutamyl transferase activity in the both cases. According to 
morphological (electron microscopic) study of liver cells enlargement of bile canaliculi and 
bile ducts was noted as well as other morphological signs of intrahepatic cholestasis. Both 
models of intrahepatic cholestasis can be used for reproduction in mice (and rats). It was 
concluded that drug-induced intrahepatic cholestasis is manifested in increased secretion of 
lysosomal enzymes into the bile. Bile components can aggravate liver cells damage by 
affecting the process of hepatocyte apoptosis and necrosis. Selective depression of Kupffer 
cells, enriched by lysososomes, reproduced in vivo (with help of gadolinium chloride) was 
followed by the aggravation of cholestasis and liver damage. Our results confirm the 
hypothesis that normal function of liver macrophages and their lysosomes play the 
important role in cholestasis development. These data can be useful in further investigation 
of the role of lysosomes of hepatocytes and liver macrophages in bile secretion and, 
possibly, in prevention of cholestasis development in medical clinics used some drugs with 
lysosomotropic action (phenothiazines, some antibiotics, polymers, iron compound, 
chloroquine etc.). 
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